FOLH1 and prostate carcinoma: Building on the LuPARP trial, where metastatic castration-resistant prostate cancer patients are treated with a combination of [177Lu]Lu-PSMA-617 and Olaparib, this study predicts Olaparib effects based on patient body weight and degree of HRD [24].